ASKA Pharmaceutical Holdings Co.,Ltd.
ASKA Pharmaceutical Holdings Co.,Ltd. Fundamental Analysis
ASKA Pharmaceutical Holdings Co.,Ltd. (4886.T) shows weak financial fundamentals with a PE ratio of 12.84, profit margin of 6.97%, and ROE of 7.37%. The company generates $70.4B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 50.8/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze 4886.T's fundamental strength across five key dimensions:
Efficiency Score
Weak4886.T struggles to generate sufficient returns from assets.
Valuation Score
Moderate4886.T shows balanced valuation metrics.
Growth Score
Moderate4886.T shows steady but slowing expansion.
Financial Health Score
Excellent4886.T maintains a strong and stable balance sheet.
Profitability Score
Weak4886.T struggles to sustain strong margins.
Key Financial Metrics
Is 4886.T Expensive or Cheap?
P/E Ratio
4886.T trades at 12.84 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 4886.T's PEG of 4.44 indicates potential overvaluation.
Price to Book
The market values ASKA Pharmaceutical Holdings Co.,Ltd. at 0.92 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 7.45 times EBITDA. This is generally considered low.
How Well Does 4886.T Make Money?
Net Profit Margin
For every $100 in sales, ASKA Pharmaceutical Holdings Co.,Ltd. keeps $6.97 as profit after all expenses.
Operating Margin
Core operations generate 6.75 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $7.37 in profit for every $100 of shareholder equity.
ROA
ASKA Pharmaceutical Holdings Co.,Ltd. generates $4.35 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
ASKA Pharmaceutical Holdings Co.,Ltd. generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
ASKA Pharmaceutical Holdings Co.,Ltd. generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
4886.T converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
12.84
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
4.44
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.92
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.90
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.20
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.40
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.07
vs 25 benchmark
ROA
Return on assets percentage
0.04
vs 25 benchmark
ROCE
Return on capital employed
0.05
vs 25 benchmark
How 4886.T Stacks Against Its Sector Peers
| Metric | 4886.T Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 12.84 | 28.25 | Better (Cheaper) |
| ROE | 7.37% | 780.00% | Weak |
| Net Margin | 6.97% | -20122.00% (disorted) | Weak |
| Debt/Equity | 0.20 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 2.40 | 4.66 | Strong Liquidity |
| ROA | 4.35% | -14687.00% (disorted) | Weak |
4886.T outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews ASKA Pharmaceutical Holdings Co.,Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation